Cardiovascular Diseases & Diagnosis

Jarkovsky J

Publications

• Research Article
  Prognostic Impact of Copeptin and Mid-Regional Pro-Adrenomedullin in Chronic Heart Failure with Regard to Comorbidities
  Author(s): Spinarova L, Spinarova M, Goldbergova-Pavkova M, Spinar J, Parenica J, Ludka O, Labr K, Malek F, Ostadal P, Vondrakova D, Tomandl J, Sevcikova J, Lipkova J, Benesova K and Jarkovsky JSpinarova L, Spinarova M, Goldbergova-Pavkova M, Spinar J, Parenica J, Ludka O, Labr K, Malek F, Ostadal P, Vondrakova D, Tomandl J, Sevcikova J, Lipkova J, Benesova K and Jarkovsky J
  
  The aim of the study is to evaluate the impact of new humoral substances: copeptin and mid- regional proadrenomedullin (MR-proADM) on one-year survival of patients with stable systolic chronic heart failure (CHF) and to compare them with AHEAD score assessing the comorbidities. The FAR NHL (FARmacology and NeuroHumoraL activation) registry is a database of patients with stable CHF (ejection fraction (EF) <50%) treated in specialized HF departments. AHEAD score is a simple bed-side mortality predictive model based on age and comorbidities. Primary endpoint after 1-year follow-up was: death or hospitalization for decompensation of HF or heart transplantation or LVAD implantation. To whole FAR NHL registry, a total amount of 1088 patients were included, in 552 of them the levels of copeptin and MR-proADM were available. Mean age was 65+12 years, mean EF was 31+9%. Patients without primar.. Read More»
  DOI: 10.4172/2329-9517.1000326

  Abstract PDF